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Delayed renal failure with extensive mesangiolysis following bone
marrow transplantation. Within two years we have had the opportunity
of observing seven leukemic children who were referred to our Pediat-
ric Nephrology Unit for delayed renal failure following bone marrow
transplantation (BMT). These children (3 to 12 years old), six with acute
lymphoblastic leukemia (ALL) and one with acute non-lymphoblastic
leukemia (ANLL), underwent BMT (4 autologous BMT, 3 allogeneic
BMT) after the first remission in two, and after the second remission in
five. Preparative regimen for BMT included cyclosphosphamide in
three, cyclosphosphamide, vepeside and cytosine A in four, and a total
body irradiation in a single dose of 10 grays (1000 R) in all of them.
Three children were treated immediately after grafting with low dose
cyclosporine for four to six months. Five to 10 months after BMT, four
patients developed a hemolytic uremic syndrome with severe hyperten-
sion. The remaining three were found to have isolated renal insufli-
ciency several months post-BMT. In the seven patients, renal biopsy
showed a uniform pattern of severe glomerular involvement character-
ized by extensive lesions of mesangiolysis associated with severe
arteriolonecrosis. A repeat biopsy performed one year later in two
patients showed severe scarring of the renal parenchyma with minor
lesions of mesangiolysis. The similarity of the pathologic features
observed suggests that the same mechanism might have been operative
in the seven patients. It is very likely that the nephropathy is related to
total body irradiation enhanced by chemotherapy. We conclude that
current treatments of high risk leukemia might become a new cause of
chronic renal failure. Further investigations are needed to know the
exact incidence of this complication.
Until recently, delayed renal complications were not men-
tioned in leukemic children [1, 2]. Since bone marrow trans-
plantation (BMT) has been introduced as a treatment of high-
risk acute leukemia, several cases of HUS occurring several
months post-BMT have been reported [3—9]. Within two years,
we have had the opportunity of observing seven leukemic
children who underwent BMT preceded by total body irradia-
tion (TB!) and who were referred to our Pediatric Nephrology
Unit for delayed renal failure associated, in 4 of them, with
hemolytic uremic syndrome. In all, renal biopsy disclosed a
uniform pattern characterized by the association of extensive
lesions of mesangiolysis and arteriolonecrosis. We wish to
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report our findings in these 7 children and discuss the possible
cause(s) of the distinctive lesions observed.
Methods
Patient population
The seven children developed a leukemia when they were 2
to II years old (Table 1): acute lymphoblastic leukemia (ALL;
6 cases) and acute non-lymphoblastic leukemia (ANLL; I
case). All patients were initially treated with various combina-
tions of chemotherapeutic agents according to the French
Cooperative Study protocols (Table 2). These agents were
associated with CNS prophylaxis consisting of intrathecal meth-
otrexate in six patients and skull irradiation in three patients. A
remission was obtained within a month in all children. Patients
1, 2, 3 and 5 and 7 relapsed three months to four years after
onset of leukemia, under treatment in patients 2, 5 and 7. For
these five children a second course of combined chemothera-
peutic agents was undertaken (Table 2), leading to a second
remission. All seven children were considered to have high risk
leukemia: five because they had relapsed (especially the 3
patients who relapsed while receiving maintenance chemother-
apy), patient 6 because of the presence of chromosomal abnor-
malities, and patient 4 because she had ANLL. BMT was,
therefore, performed 5 months to 4½ years after onset of
leukemia. Patients 4, 5and 7 received an allogeneic BMT while
patients 1, 2, 3 and 6 received an autologous BMT because of
the absence of matched donors. All children were prepared for
BMT with a new course of intensive chemotherapy: cyclos-
phosphamide alone on the third and fourth day before BMT (60
mglkglday) in patients 4, 5 and 6, and cyclosphophamide
associated with cytosine-arabinoside (200 mglm2/day) for five
days and vepeside (200 mglm2/day) for three days in patients I,
2, 3 and 7. Furthermore, a TBI of 10 grays (1000 R) in one
fraction (with 8 grays on the chest) was performed the day prior
to transplantation.
After evidence of engraftment, the post-transplant course of
the four children with autologous BMT (pts 1, 2, 3 and 6) was
uneventful for a few months; these children had normal renal
function. During this period patients 1, 2 and 3 received 6
mercaptopurine daily, associated with vincristine once a month
in patients 2 and 3. Patient 6 did not receive any chemotherapy
post-transplantation. After grafting, the three children with
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allogeneic BMT (pts 4, 5 and 7) were treated for four to six
months with cyclosporine to prevent graft-versus-host (GVH)
disease. Cyclosporine was administered at a dose of 3 to 6.5 mgI
kg/day and plasma trough levels measured by RIA never
exceeded 50 to 100 ng/ml, except once in each patient when
they reached a maximum of 220 ng/ml associated with a
transient episode of cyclosporine nephrotoxicity in only one
patient (pt 7). An episode of acute nephrotoxicity was also
observed in patient 5 with no modification of plasma trough
levels. In both cases these episodes, characterized by an
increase in creatinine and blood pressure, occurred four months
post-BMT and subsided after withdrawal of cyclosporine. In
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Table 1. Clinical findings
Patient
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I 2 3 4 6 7
6 5
150/110
184
6 7
150/90
127
20
l0
170/110
181
29
2
140/100
135
25
7
110/70
95
1.3
micro
8
+
ND
175,000
34
120/80
320
0.6
macro
8.4
no
100,000
Type of leukemia ALL ALL ALL ANLL ALL ALL ALL
Age at discovery yrs 3 3 5 3 6 II 2
BMT type autologous autologous autologous allogeneic allogeneic autologous allogeneic
Delay between onset of 53 20 54 II 50 5 8
leukemia and BMT
months
Delay between BMT and
renal symptoms
months
BP mm Hg
Serum creatinine
p.mo!/liter
Creatinine clearance
ml/min/!.73 m2
Proteinuria glday
Hematuria
Hb gidi
Schizocytosis
Haptoglobin
Platelets mm3
Follow-up period from
onset of renal (death:
symptoms months relapse of
leukemia)
BP mm Hg
Serum creatinine
j.unol/liter
Creatinine clearance 51 8 70 25 80 ND
mI/mini!. 73 m2
Proteinuriag/day 0 0.15 0 0.54 0 0
Hematuria no no no ND no no
30
100/60
94
0.24
micro
8.6
+
ND
37,000
24
ND
0.56
no
7.3
+
ND
300,000
3
ND
no
7.7
no
ND
151,000
18
120/80
100
0
no
10.1
no
ND
29,000
18
0
no
7.4
+
178,000
17
controlled
531
12
110/50
64
3
85/50
193
112/64
123
100/60
83
Abbreviations are: ALL, acute lymphoblastic leukemia; ANLL. acute non-lymphoblastic leukemia: BMT, bone marrow transplantation; BP,
blood pressure; Hb, hemoglobin; ND, not done.
Table 2. Chemotherapy
Patient
I 2 3 4 5 6 7
Vincristine + + + + + + +
Vindesine + + + +
L-asparaginase + + + + + +
Daunomycin + + + + + +
Rubidazone +
Doxorubicin +
Cytosine-arabinoside + + + + + + +
M-AMSA + +
Etoposide (VP 16) + + + +
Teniposide (VM 26) + +
Methothrexate + + + + + +
Guanylhydrazone +
Hydroxyurea +
Cyclophosphamide + + + + + + +
6.Mercaptopurine + + + + +
Azathioprine +
Cyclosporine + + +
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addition, in patient 5, RBC, WBC and platelet counts remained
low because of bad engraftment probably related to a human
immunodeficiency virus (HIV) infection which was discovered
after grafting.
Pathology study
Renal biopsies were performed in all children and follow-up
biopsies were obtained in patients I and 4. For light (LM) and
electron microscopic (EM) studies, standard procedures were
used. Frozen sections of kidney specimens were tested for the
presence of IgG, IgA, 1gM. Clq, C4, C3, albumin and fibrin
using direct immunofluorescence (IF) methods.
Results
Clinical renal findings
Renal symptoms developed in all patients. Two types of
clinical presentation were observed (Table 1).
a) Patients 1 through 4 presented abruptly with a he,nolytic
uremic syndrome (HUS) 5 to 7 months after BMT. At referral,
they had severe hypertension associated with cardiac failure in
two (pts I and 4). Renal failure was moderate (with serum
creatinine ranging from 127 to 184 tmol/liter as well as protein-
uria (0.24 to 1.3 glday). Hematuria was present in all but one.
There was a micro-angiopathic hemolytic anemia requiring red
blood cell transfusion in all cases. Platelet count was below
normal range in three children. A treatment of hypertension
was undertaken with enalapril administered in all cases and
nifedipine added in two. After normalization of platelet count,
which occurred within one month, percutaneous renal biopsies
were performed in the four patients. A treatment by salicylate
(4 mg/kg/day) and dipyridamole (5 mg/kg/day) was then initi-
ated. Patient 2 died from a relapse of his leukemia three months
after onset of renal symptoms. The three other patients re-
mained leukemia-free 15 to 30 months after BMT. Renal out-
come was variable. In patient 3, blood pressure remained
difficult to control and GFR decreased progressively, leading to
terminal renal failure within one year. With a follow-up of two
years, patient 4 had completely recovered with normal GFR
(serum creatinine: 65 smol/liter; creatinine clearance: 100 ml/
min/l.73 m2), no proteinuria and no hematuria. Blood pressure
remained normal after withdrawal of enalapril. Patient I im-
proved considerably. At last follow-up two years later, he had
neither proteinuna nor hematuria. Blood pressure was stable
with low dose enalapril (2.5 mg/day). However, he has a mild
decreased GFR (creatinine: 99 smol/liter; creatinine clearance:
55 mllmin/l.73 m2). A repeat biopsy has been performed one
year after onset of HUS in patients 4 and I.
b) Patients 5, 6 and 7 presented with rena/failure. In patient
5, decreased GFR (serum creatinine: 95 mol/liter; creatinine
clearance: 30 mI/mm/I .73 m2) with moderate proteinuria (1 g/
day) was discovered ten months post-BMT. There was no
hematuria and blood pressure was normal. There were no signs
of hemolysis. Red blood cells and platelet counts were low but
had remained low after BMT (vide supra). Because of thrombo-
cytopenia and increased clotting time, renal biopsy was delayed
for seven months. Following renal biopsy, GFR progressively
decreased and at last examination, 16 months after discovery of
renal symptoms, serum creatinine was 195 smol/liter with a
creatinine clearance of 29 mI/mm/I .73 m2. In patient 6, a
decreased GFR (serum creatinine: 320 mol/liter) was found
two months after BMT while the patient was receiving nephro-
toxic drugs (vancomycin, amphotericin B and acyclovir). Blood
pressure was normal; there was no hematuria and no protein-
uria. RBC and platelet counts had remained stable. There were
no signs of hemolysis and no schizocytosis. After withdrawal of
all nephrotoxic drugs, GFR improved (serum creatinine: 84
mol/liter; creatinine clearance: 80 mI/mm/I .73 m2) within two
months. Thereafter, GFR progressively decreased again and
lead to stable chronic renal failure (serum creatinine: 123 smol/
liter) one year after onset of renal symptoms. A renal biopsy
was then performed. At seven months post-transplantation
patient 7 developed a moderate renal insufficiency (serum
creatinine: 90 mol/liter) associated with a transient hemolytic
anemia, but without proteinuria, hematuria or hypertension. A
renal biopsy was then performed. Three months later renal
function remained impaired but stable.
Pathology
A. Initial biopsy. 1) Light microscopy. The lesions were
identical in all patients and were characterized by severe
glomerular and arteriolar changes.
In the glomeruli, the most striking lesion was a ballooning of
the lobules of the tufts affecting a variable number of glomeruli
(pt I 80% pt 2 90%; Pt 3 100%; Pt 4 70%; Pt 5 25%; pt 6 50%;
Pt 7 80%). In the affected glomeruli, which were enlarged and
hypocellular, most of the lobules were involved (Fig. 1). The
expanded lobules were filled with a spongy material composed
of fine strands of mesangial matrix arranged in a trabecular
pattern (Fig. 2). With PAS and silver methenamine stains, this
fibrillary material appeared clearly as the result of expansion of
the mesangial regions extending peripherally along the inner
aspect of the intact glomerular basement membrane. The sub-
endothelial space was considerably widened either giving a
double contour appearance to the capillary walls or almost
completely obstructing the lobules. A few narrowed capillary
lumens, sometimes lined by apparently normal endothelial
cells, were visible in the middle of this network. Very occa-
sional capillary lumens were distended with red blood cells,
while most appeared bloodless. Red blood cells were also seen
trapped in the fibrillary areas together with scattered fusiform
mesangial cells and cellular debris. The appearance was that of
a disintegration of the mesangial matrix. The unaffected lobules
showed a typical aspect of thrombotic microangiopathy with an
increase in mesangial matrix and a widened subendothelial
space. In patients S and 6, in addition to the glomeruli with
mesangiolytic changes there were some ischemic and some
fibrotic glomeruli.
Arteriolar changes were present in all seven patients. They
were severe in patients 1, 2, 3, 5 and 6 and less marked in
patients 4 and 7. These changes were characterized by marked
narrowing of the lumens with a widening of the subendothelial
space due to a mucoid thickening of the intima. In some
arterioles the lumens were occluded by fibrinoid material con-
taining occasional foam cells. The myocytes of the muscular
layer were swollen and some were necrotic, replaced by protein
deposits buldging into the periphery of the arteriolar wall (Fig.
I). In addition to the glomerular and vascular changes, variable
degrees of interstitial edema were present in patients 1, 2, 3, 4
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Fig. 1. Severe glomerular involvement characterized by an expansion
of the mesangial regions and a double contour appearance of the
capillary walls. Deposits (arrows) are present into the periphery of the
arteriolar wall. Light microscopy. Jones silver methenamine stain,
x 450.
and 7. Interstitial fibrosis and a few groups of atrophic tubules
were observed in patients 5 and 6.
Inconclusion, the seven patients showed extensive lesions of
mesangiolysis associated with diffuse arteriolonecrosis.
2) Electron microscopy (pis I, 3, 5 and 6). Severe glomerular
lesions were observed in all glomeruli studied (2 to II per
patient). They consisted ofuneven thickening of capillary walls
leading to more or less severe capillary lumens obstruction
associated with focal loosening of mesangial stalks. Both
changes were related to the accumulation of a clear heteroge-
neous material both in the subendothelial zone and in the
mesangial areas (Fig. 3).
Lesions of the capillary walls were nearly diffuse but varied
in severity. Flocculent deposits were located on the internal
side of the normal lamina densa and separated from the endo-
thelial cell by a thin layer of newly formed basement membrane
(Fig. 3). Most endothelial cells were enlarged with abundant
perinuclear cytoplasm rich in rough-surfaced endoplasmic re-
ticulum, a thick continuous cytoplasmic layer lining the periph-
ery of the capillary loops (Fig. 3). No necrotic cells were
disclosed. In the reduced capillary lumens, occasional mono-
Fig. 2. Trabecular pattern of expanded mesangial matrix. Light mi-
croscopy. Jones silver methenamine stain, x 1350.
cyte-macrophages or polymorphonuclear cells and platelet ag-
gregates were observed. Podocytes were often normal even
along thickened capillary loops and only focal effacement of
foot processes was present (Fig. 4).
Mesangial lesions were characterized by both a massive
edematous infiltration of mesangial stalks with disruption and
fading of strands of mesangial matrix only identified on silver
impregnated sections, and changes in mesangial cells concern-
ing their shape, structure and connections (Fig. 4). Some
mesangial cells were elongated with a little cytoplasm contain-
ing numerous bundles of myofibrils and dense attachment
bodies. Others were roundly shaped with an abundant cyto-
plasm containing rare myofibrillar structures or attachment
bodies. They had prominent rough-surfaced endoplasmic retic-
ulum and hypertrophied Golgi apparatus, and were focally
surrounded by a thin discontinuous layer of newly synthesized
basal lamina. In a few mesangial cells, the entire cytoplasm was
filled with numerous vacuoles containing clear or osmiophilic
droplets but necrotic cells were exceptionally observed. De-
tached mesangial cells appeared as isolated cells irregularly
distributed within the insudative material where cytoplasmic
processes, entire or fragmented red blood cells, thin unorga-
nized strands of fibrillar material and curvilinear structures
could also be seen.
Arteriolar changes consisted of: I) massive round electron-
i'- .-,'.
-: •
1'
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Fig. 3. Accumulation of a clear material both in the mesangial areas (M) and in the subendothelial zone. Presence ofa newly formed layer of
basement membrane (arrows). Electron microscopy. Silver methenamine impregnation, X 2000.
dense deposits unevenly distributed at the sites of necrotic
smooth muscle cells, each regularly surrounded by basement
membrane material; 2) various degenerative changes of smooth
muscle cells; 3) clear heterogeneous deposits located in the
subendothelial space; and 4) enlargement of endothelial cells
(Fig. 5). Most peritubular capillary endothelial cells were also
hypertrophied.
3) Immunofluoresce,we microscopy. The biopsy specimens
were examined by IF in six cases (pts 1, 2, 4, 5, 6 and 7). They
all showed the same pattern of protein deposits by IF. There
were extensive deposits of fibrin and 1gM on all glomeruli and
very peculiar lesions of the arterioles. These lesions consisted
of coarse granular deposits of C3 arranged in a pearl-like pattern
on the muscular layer of all the arterioles (Fig. 6). These C3
deposits were isolated in patients 2 and 6, and were associated
with Clq and 1gM in patients 1, 4, 5 and 7. C4 was also present
in the same location in patient 4.
B. In repeat biopsies, performed in patients I and 4 by LM,
the ,nesangiolvtic changes had almost completely disappeared.
In both patients one-third of the glomeruli showed diffuse
mesangial hypercellularity with moderate increase in mesangial
matrix but no capillary wall abnormality. Another third of the
glomeruli were completely fibrotic and the last third showed an
ischemic pattern with wrinkling of the glomerular basement
membranes. In addition to these glomerular changes there was
mild interstitial fibrosis and extensive tubular atrophy. Intimal
thickening of the arterioles was present in both cases but was
less marked than on initial biopsies.
By EM performed in patient I, most glomeruli were ischiemic
or fibrotic. In the others, mesangial cell proliferation was
associated with abundant mesangial matrix without any edem-
atous insudation (Fig. 7). However, segmental lesions similar to
those observed on initial biopsy were disclosed in three glomer-
uli (Fig. 8). Round, well circumscribed, electron-dense deposits
were observed within the muscular layer of some arterioles and
were focally associated with clear subendothelial deposits.
By IF, performed in patient 1, peripheral deposits of 1gM
were seen in the glomeruli and granular deposits of C3 were
present along the arteriolar walls.
Discussion
The seven patients reported in the current study were high-
risk leukemic children who had been intensively treated by
chemotherapy prior to bone marrow transplantation (BMT).
BMT was immediately preceded by total body irradiation (TBI)
associated with a new course of intensive chemotherapy. All
children were referred to the Pediatric Nephrology Unit be-
cause of the occurrence of renal failure. Four patients presented
with hemolytic uremic syndrome with severe hypertension, and
one patient presented with renal failure and a transient hemo-
4:'
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Fig. 4. Massive edematous infiltration of mesangial stalks and peripheral capillary loops. Various changes in detached mesangial cells (arrows).
Enlargement of the endothelial cells of the adjacent capillary loop (*). Electron microscopy. Uranyl acetate and lead citrate, x 2800.
lytic anemia that developed five to seven months post-BMT. In
the remaining two there were no signs of hemolysis and renal
failure developed progressively. The common denominator of
the seven patients is the renal biopsy findings characterized by
the association of diffuse arteriolonecrosis with extensive le-
sions of mesangiolysis. Mesangiolysis has been defined by
Morita and Churg [101 as a dissolution or attenuation of
mesangial matrix and degeneration of mesangial cells. Accord-
ing to Morita and Churg, focal and segmental lesions of mes-
angiolysis may be present in a wide variety of glomerular
diseases, from those caused by toxins (snake bite) to several
forms of glomerulonephritis including thrombotic microangiop-
athy (TMA), transplant rejection and radiation nephritis. In our
patients the lesions of mesangiolysis affected most of the
glomeruli and most of the lobules in each glomerulus, and
appeared to be an "explosive" form of TMA.
These homogeneous pathologic features suggest that a similar
mechanism might have been operative in all patients, but
several factors may be involved. It seems quite obvious that in
these children the nephropathy is not related to leukemia itself
since all children had been leukemia-free for several months
when renal failure occurred. Moreover, delayed renal symp-
toms are not reported among the complications of leukemia [2,
11]. Human immunodeficiency virus infection, which was
present in only one of our patients, is not known to be
associated with this type of nephropathy [12]. Therefore, it is
very likely that the nephropathy is related to the treatment of
leukemia. Among the drugs received by these patients some are
known to be nephrotoxic. The role of cyclosporine can reason-
ably be dismissed. First, cyclosporine was administered in only
three of the seven children and was withdrawn one to six
months before onset of the renal disease. Furthermore, al-
though a few cases of HUS have been reported as a conse-
quence of cyclosporine toxicity [3, 13—19] most occurred soon
after transplantation and none have shown lesions of mesan-
giolysis. Among the chemotherapeutic agents, mitomycin C is
the only one which is known to be responsible for the delayed
development of a HUS [20] associated with extensive lesions of
mesangiolysis [21], but none of our children received mitomy-
cm C. Several cases of delayed HUS or TTP have, however,
been reported following the administration of other chemother-
apeutic agents for the treatment of malignancies [20, 22—30]. In
all these instances, when pathology was available, the lesions
observed in the kidneys were described as typical of thrombotic
microangiopathy (TMA), the classical lesion of HUS, and no
lesions of mesangiolysis are mentioned. We have recently
observed such a case. However, Tuttle et al [31] reported a
patient who received nitrosurea therapy and developed renal
f)tj1r&.Jç -: f! Sc
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Fig. 5. Severe arteriolar involvement 4'ith large suhendothelial hete-
rogenous deposits (*) and peripheral, round electron-dense deposits in
the monocytes (arrows). Electron microscopy. Uranyl acetate and lead
citrate, x 2550.
Fig. 6. Coarse granular Cl deposits in the muscular layer of a small
artery. Immunofluorescence. Anti-C3 serum, x 450.
insufficiency with extensive basement membrane splitting and
capillary aneurysm formation.
By contrast, high dose irradiation seems to be able to induce
delayed lesions similar to the ones we observed in our patients
[321. If typical cases of HUS with TMA have been reported in
several cases of abdominal irradiation, associated [33—391 or not
[29, 40—42] with chemotherapeutic agents, lesions of mesan-
giolysis have also been observed, although not always recog-
nized as such. Zuelzer, Palmer and Newton [43] 39 years ago,
when illustrating typical lesions of what we today call mes-
angiolysis, considered their patients (3 children) as having an
"unusual type of GN". Birembault et al [44] described a
patient, very similar to our patients 5and 6, who presented with
renal failure and proteinuria but without signs of hemolysis, and
showed lesions of mesangiolysis. Mostofi described the same
pattern under the name of "nephroglomerulosis" in delayed
complications of radiation nephritis [45].
Lastly, a few cases of HUS occurring several months after a
BMT preceded by TBI per-formed for leukemia or for other
causes [3—9] have been published. The lesions observed by
Bergstein et al [6] and Guinan et al [91 are identical to the ones
we have seen in our patients. In the other reports, although the
diagnosis of TMA is asserted when pathology is available, the
micrographs published seem to show more or less extensive
lesions of mesangiolysis [4, 7].
Fig. 7. Repeat biopsy. Mesangial cell proliferation with normal capil-
lary walls. Electron microscopy. Silver methenamine impregnation, x
1200.
The incidence of such a complication in BMT recipients is
difficult to assess. However, it seems to develop in a meaningful
percentage of patients. According to Guinan et al [9], 14 of 31
evaluable pediatric patients treated with multiagent condition-
ing plus TBI prior to BMT developed anemia and renal insuf-
ficiency three to seven months post-BMT. The experience of
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improved in 2. However, follow-up biopsies, performed in the
latter 2 children, showed scarring of the renal parenchyma with
an almost total disappearance of the lesions of mesangiolysis
and mesangial hypercellularity in the unscarred glomeruli. This
hypercellularity could be interpreted as a repairing process.
In conclusion, children who undergo a BMT with TB! should
be followed closely after grafting because the current treat-
ments of high risk leukemia might become a new cause of
chronic renal failure and nephrologists should be aware of this
possible radiation-induced complication. However, modifica-
tions of BMT conditioning might be able to prevent renal
involvement.
Note added in proof
Since the submission of this paper, a further paper on this subject has
been published. Chappell ME, Keeling DM, Prentice HG, Sweney P:
Haemolytic uraemic syndrome after bone marrow transplantation: an
adverse effect of total body irradiation. Bone Marrow Transplant
3:339—347, 1988.
Acknowledgments
Fig. 8. Repeat biopsy. Segmental glomerular lesions characterized by
the presence of flocculent deposits between the endothelial cells and the
focally wrinkled basement membrane. Electron microscopy. Silver
methenamine impregnation, x 1600.
one of us (GL) confirms this high incidence. Among 11 children
who underwent autologous BMT between 1984 and 1986 in
Hôpital St. Louis, Paris, and who survived more than six
months, six developed renal symptoms. Four patients (3 with
HUS and I with renal failure) are included in the current study
and two who presented with HUS have no pathology available.
By contrast during the same period, six syngenic BMT without
TB! were performed and none of the patients developed renal
symptoms.
We therefore suggest that irradiation, mainly TB!, delivered
in one single dose of 10 grays and probably enhanced by
chemotherapy, is the most important factor responsible for this
type of renal involvement. This hypothesis is confirmed by the
fact that, based on our observations, the hematologists of St.
Louis Hospital in Paris have changed both the conditioning
(withdrawal of cyclophosphamide which has been replaced by
aracytine and melphalan) and the schedule of irradiation before
BMT by fractioning the doses of TB! (2 grays twice a day on 3
consecutive days). Since the beginning of 1987, of 10 children
who underwent autologous BMT with this new protocol and
were followed for more than six months post-TBI, none devel-
oped delayed renal failure.
The pathogenetic mechanism of the lesions observed is
unknown. However, it is likely that the involvement of the
mesangium is secondary to a radiation-induced endothelial cell
injury. As suggested by Bergstein et al [6]. the delay between
irradiation and the onset of renal symptoms may he explained
by the slow replication of normal endothelial cells.
The long-term outcome of this renal complication of BMT
preceded by TB! seems severe since most patients reported
died or progressed to end-stage renal failure [4—8]. In the
current study, of the five children followed for more than one
year after onset of renal symptoms, renal function deteriorated
rapidly in one patient, remained impaired but stable in 2 and
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